Recent Recurrent Breast Cancer News

Tecentriq™ Plus Abraxane® Effective Combo in Difficult to Treat Breast Cancer (June 30, 2016)

The combination of the immune stimulating agent Tecentriq™ (atezolizumab), plus the chemotherapy agent Abraxane® (nab-paclitaxel) is effective in providing anti-cancer responses among patients with... Continue Reading

Directly Involving Patients Drives Participation in Metastatic Breast Cancer Study (June 22, 2016)

A clinical study to accelerate research in metastatic breast cancer has rapidly enrolled participants through direct collaboration with patients. These results were recently presented at the 2016 annual... Continue Reading

ASCO Publishes Breast Cancer Survivorship Guidelines (January 25, 2016)

The American Society of Clinical Oncology (ASCO), in collaboration with the American Cancer Society (ACS), have released updated guidelines regarding follow-up care for breast cancer survivors. The updated... Continue Reading

Blood Test May Predict Cancer Recurrences Earlier than Standard Methods (October 26, 2015)

A blood test that can detect circulating DNA from cancer cells appears to accurately predict the risk of a breast cancer recurrence 8 months earlier than standard detection methods among women with high-risk... Continue Reading

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer (October 9, 2015)

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive... Continue Reading

Radiation Essential to Controlling Long-Term Recurrence in Women With Early Form of Breast Cancer (October 1, 2015)

Doctors have reported that rates of breast cancer recurrences continue to increase, even after 12 years, among patients with ductal carcinoma in situ (DCIS) who do not receive radiation therapy as part... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (August 4, 2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered... Continue Reading

Study Suggests Faslodex® Could Become New Standard First-Line Treatment of Metastatic Breast Cancer (March 9, 2015)

Faslodex® (fulvestrant) at a 500-mg dose has been demonstrated to be superior to Arimidex® (anastrozole) as first-line therapy for advanced hormone receptor–positive breast cancer in the phase II FIRST... Continue Reading

The Novel Small Molecule Pictilisib May Benefit Women with Advanced Breast Cancer (March 5, 2015)

The addition of the investigational drug pictilisib to Faslodex® (fulvestrant) has been demonstrated to delay the time of cancer in women with advanced or metastatic breast cancer to be positive for both... Continue Reading

Breast Cancer Research: Have We Made Progress? (January 27, 2015)

Published results from research studies in breast cancer in the last year represent several practice changing milestones. CancerConnect News coverage of advances in the management of breast cancer included... Continue Reading

Next Page »